Alexion/P&G Pexelizumab Failed Phase III Could Compromise Development Partnership
This article was originally published in The Pink Sheet Daily
Executive Summary
The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.